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19q13.11 cryptic deletion: description of two
new cases and indication for a role of WTIP
haploinsufficiency in hypospadias
Simone Gana1,5, Pierangelo Veggiotti2,5, Giusy Sciacca1, Cristina Fedeli2, Anna Bersano2, Giuseppe Micieli2,
Mohamad Maghnie3, Roberto Ciccone1,2, Elena Rossi1, Katie Plunkett4, Weimin Bi4, Vernon R Sutton4
and Orsetta Zuffardi*,1,2
Developmental delay/intellectual disabilities, speech disturbance, pre- and postnatal growth retardation, microcephaly, signs of
ectodermal dysplasia, and genital malformations in males (hypospadias) represent the phenotypic core of the recent emerging
19q13.11 deletion syndrome. Using array-CGH for genome-wide screening we detected an interstitial deletion of chromosome
band 19q13.11 in two patients exhibiting the recognizable pattern of malformations as described in other instances of this
submicroscopic genomic imbalance. The deletion detected in our patients has been compared with previously reported cases
leading to the refinement of the minimal overlapping region (MOR) for this microdeletion syndrome to 324 kb. This region
encompasses five genes: four zinc finger (ZNF) genes belonging to the KRAB-ZNF subfamily (ZNF302, ZNF181, ZNF599, and
ZNF30) and LOC400685. On the basis of our male patient 1 and on further six male cases of the literature, we also highlighted
that larger 19q13.11 deletions including the Wilms tumor interacting protein (WTIP) gene, proximal to the MOR, results in
hypospadias making this gene a possible candidate for this genital abnormality due to its well-known interaction with WT1.
Although the mechanism underlying the phenotypic effects of copy number alterations involving KRAB-ZNF genes at 19q13.11
has not clearly been established, we suggest their haploinsufficiency as the most likely candidate for the phenotypic core of the
19q13.11 deletion syndrome. In addition, we hypothesized WTIP gene haploinsufficiency as responsible for hypospadias.
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INTRODUCTION
Microdeletion of 19q13.11 is an emerging syndrome mainly identified
due to widespread use of genome-wide arrays. Patients share some
common and indeed distinctive findings, and this deletion could
potentially represent a clinically identifiable syndrome mainly char-
acterized by developmental delay/intellectual disabilities (DD/ID),
speech disturbance, pre- and postnatal growth retardation, microce-
phaly, signs of ectodermal dysplasia, and genital malformations in
males (hypospadias). By using array-CGH for genome-wide screening,
we have detected an interstitial deletion of chromosome 19q13.11 in
two patients exhibiting the recognizable pattern of malformations as
described in other instances of this cryptic genomic imbalance.1–3
The deletion detected in our patients has been compared with the
five previously published cases and two reported in the Database of
Chromosomal Imbalance and Phenotype in Humans using Ensemble
Resources (DECIPHER), leading to the refinement of the critical
region for this microdeletion syndrome to 324 kb.
PATIENTS AND METHODS
Clinical report
Patient 1. This patient, a boy, was the only child born to non-consanguineous
healthy parents. Family history was unremarkable. During pregnancy, fetal
ultrasound scans at 30 weeks of gestation revealed intrauterine growth
retardation and a ventricular septal defect. Cesarean section was performed
at 34 weeks of gestation, due to fetal distress. Birth weight was 1590 g (o3rd
centile). Apgar scores were 8 at both 1 and 5min. Some minor dysmorphic
facial features, abnormalities of extremities (second and third finger syndactyly
of the right hand and bilateral two to four partial syndactyly of toes), and
proximal hypospadias were observed at birth. The early infancy was compro-
mised by feeding difficulties and failure to thrive. At 2 years of age, a partial
growth hormone (GH) deficiency was diagnosed (GH peak of 7.23 ng/ml after
glucagon and of 2.01ng/ml after arginine, normal value 410ng/ml), which
required GH treatment. Delayed milestones were noticed in the first months of
life (free walking at 18 months). From the age of 4 he presented abnormal
dystonic postures of the lower limbs. The dystonia, involving initially only the
lower limbs, progressed to generalized dystonia, complicated by tremor,
and non-epileptic myoclonus, over the following years. Generalized and
oromandibular dystonia did not respond, or only partially responded, to oral
antidystonic treatment (particularly, pimozide was withdrawn due to long Q–T
interval after a few days of treatment), botulinum toxin treatment, and
intrathecal baclofen.
At 14 years of age, on physical examination, head circumference was 47 cm
(o 2nd centile), height 124 cm (o3rd centile), and weight 27 kg (o3rd
centile). He presented severe ID with absent speech and severe dystonic
tetraplegia, resulting in bilateral ankle deformity, bilateral hip luxation,
and multiple muscle contractures (Figure 1a). Continuous spasmodic
Received 10 October 2011; revised 20 December 2011; accepted 6 January 2012; published online 29 February 2012
1Department of Molecular Medicine, Medical Genetics, University of Pavia, Pavia, Italy; 2Fondazione IRCCS C. Mondino, Pavia, Italy; 3Department of Pediatrics, IRCCS Giannina
Gaslini - University of Genova, Genova, Italy; 4Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA
*Correspondence: Professor O Zuffardi, Department of Molecular Medicine, Medical Genetics, University of Pavia, 27100 Pavia, Italy. Tel: +39 0382 987 733;
Fax: +39 0382 525 030; E-mail: zuffardi@unipv.it
5These authors contributed equally to this work.
European Journal of Human Genetics (2012) 20, 852–856
& 2012 Macmillan Publishers Limited All rights reserved 1018-4813/12
www.nature.com/ejhg
oromandibular dystonia caused life-threatening breathing difficulties
(Figure 1b). Dysmorphologic evaluation revealed: narrow face, thick medially
sparse eyebrows, hypertelorism, columella below alae nasi, thin lips, retro-
gnathia, low set ears with large lobules (Figure 1b). In addition, cutis aplasia in
midline of scalp was noted (Figure 1c). Both hands had long fingers and
presented bilateral clinodactyly of the fifth finger. Moreover, second and third
finger syndactyly of the right hand and bilateral two to four partial syndactyly
of toes were present.
The laboratory examinations including routine blood and urine tests
were normal. Brain magnetic resonance imaging (MRI) revealed mild enlarge-
ment of the lateral ventricles. Karyotype, subtelomeric fluorescence in situ
hybridization (FISH), FISH for the DiGeorge syndrome critical region,
and molecular investigations for dystonia (mutations of the DYT1 gene) gave
normal results.
Patient 2. This patient, a girl, was the third born to unrelated healthy parents.
She had two older healthy siblings, a brother and a sister, respectively. There
was no history of hereditary disorders in her family. Two relatives, second-
degree and third-degree, respectively, had a history of learning disabilities. The
pregnancy was complicated by intrauterine growth retardation, whereas the
spontaneous vaginal delivery, at 38 weeks of gestation, was uncomplicated.
Birth weight was 1.9 kg (o3rd centile). The neonatal and postnatal periods
were uneventful. A sacral dimple was noted at birth, however, no occult spinal
dysraphism was identified through spine MRI. The early infancy was compro-
mised by failure to thrive without evident feeding difficulties. She presented
moderate global DD with motor and verbal domains predominantly impaired.
At 8 years of age, on physical examination, head circumference was 48 cm
(o 2nd centile), height 120 cm (o3rd centile), and weight 27 kg (50th centile).
She presented moderate ID with impaired expressive language, partially due to
abnormal tongue movement consistent with oral dyspraxia, and hoarse voice.
Neurological examination revealed poor balance with clumsiness, dysdiadocho-
kinesia and mild hypotonia. She wore glasses for astigmatism. Dysmorphologic
evaluation revealed: round face with narrow and up-slanting palpebral fissures,
thick medially sparse eyebrows, puffy cheeks, columella below alae nasi,
short philtrum, thin lips, hypodontia with coarse and rudimental shaped
teeth, small mandible, large ear lobules, long fingers with short fifth digits
bilaterally (Figures 1d and e). No other abnormalities were detected on clinical
examination.
Array-CGH
Array-CGH was performed on patient 1 and his parents using the Agilent kit
4x180K (Human Genome CGH Microarray, Agilent Technologies, Santa Clara,
CA, USA) according to the manufacturer’s protocol. For patient 2, array-CGH
was performed using a custom-designed 4x180K Agilent array V8.1, and data
were analyzed as described previously.4,5
CNVs reported in the Database of Genomic Variants http://projects.tcag.ca/
variation/ and in-house databases of benign CNVs were excluded from further
analysis. Genomic positions are referred to the Human Genome March 2006
assembly (hg18).
Fluorescence in situ hybridization
FISH was performed on patients’ parents by using BAC RP11-630G5
(patient 1), and RP11-770P14 (patient 2), mapping within the deleted regions.
RESULTS
Array-CGH analysis identified a 1.7Mb deletion at 19q13.11-q13.12 in
patient 1 (proximal breakpoint located between 39 608 712 and
39 626 575 bp, distal breakpoint located between 41 330 875 and
41 353 676 bp), and an B2.63-Mb interstitial deletion at 19q13.11-
q13.12 in patient 2 (proximal breakpoint located between 39 735 455
and 39803 651 bp, distal breakpoint located between 42436 832 and
42 595 049 bp; Figures 2a and b). The two informative microsatellites
(D19S425 and D19S893) showed that the deletion in patient 1
occurred on the maternal chromosome 19 (Figure 2c).
Figure 1 Patient 1 at 14 years of age showing dystonic tetraplegia (a) with severe oromandibular impairment (b), thin face, thick eyebrows medially sparse,
hypertelorism, columella below alae nasi, thin lips, low set ears with large lobules (b), and cutis aplasia in midline of scalp (c). Patient 2 at 8 years of age
showing round face with narrow and up-slanting palpebral fissures, thick eyebrows medially sparse, puffy checks, columella below alae nasi, short philtrum,
thin lips, hypodontia with coarse and rudimental shaped teeth (d), small mandible, and large ear lobules (e).
19q13.11 cryptic deletion
S Gana et al
853
European Journal of Human Genetics
Parental FISH analysis confirmed that both deletions were de novo.
Possible insertional translocations were also excluded in all parental
samples (data not shown).
DISCUSSION
We identified two unrelated individuals harboring overlapping de novo
deletions of the long arm of chromosome 19 of about 1.7 and 2.6Mb,
respectively.
Five cases with 19q13.11 deletion have been published1–3 with two
additional ones present in the DECIPHER database (patients 127 and
3776). Only one of these patients had a cytogenetically visible
deletion.3 Malan et al, describing the first three patients, indicated
the recognizable clinical pattern of this chromosome imbalance and
Schuurs-Hoeijmakers et al comparing the clinical features of 19q13.11
deletion cases narrowed the critical region to 750 kb.1,2 Typical
features, that were also present in both of our patients, are DD/ID,
speech disturbance, microcephaly, pre- and postnatal growth retarda-
tion, and some signs of ectodermal dysplasia represented in our cases
by cutis aplasia in midline of scalp and sparse eyebrows in patient 1
and by sparse eyebrows and teeth anomalies in patient 2. Consistent
with the notion that male genital abnormality is one of the important
recognizable characteristics of this syndrome, hypospadias is observed
in all the male patients including patient 1, the four previously
published ones and the two DECIPHER database cases. In addition,
all the patients present some facial dysmorphisms, although a peculiar
facial phenotype cannot be defined. Extremity anomalies (mainly
clinodactyly of the fifth finger and syndactyly) are common but not
necessarily present in all individuals. Table 1 summarizes clinical
findings of our patients and of the previously published ones.
The deletion reported in all the previous cases overlapped with the
deletions in our patients, leading to a further narrowing of the
minimal overlapping critical region to a size of 324 kb, located
between nucleotide position 39 803 651 and 40 127 916 on chromo-
some 19q (UCSC Genome Browser, Build 36.1, hg18; Figure 3). Hence
the minimal overlapping region (MOR) includes five genes,
the ZNF302, ZNF181, ZNF599, LOC400685, and ZNF30. Predictions
of candidate genes are difficult as the function of some of them is still
largely unknown. Schuurs-Hoeijmakers et al had considered potential
candidate genes LSM14A, UBA2, and, to a lesser extent, the four zinc
finger (ZNF) genes belonging to the KRAB-ZNF subfamily (ZNF302,
ZNF181, ZNF599, and ZNF30).2 The first two genes are not included
in deleted regions in our cases. These KRAB-ZNF genes might be
considered the strongest candidate for 19q13.11 microdeletion
syndrome, though, to date, the role of haploinsufficiency for these
genes in human diseases is not clearly established. The KRAB-ZNF
genes constitute the largest single family of transcriptional regulators
in mammals and are expressed in all human tissues being involved in
the embryonic development, cell differentiation, cell proliferation,
apoptosis, neoplastic transformation, and cell cycle regulation.6,7
However, despite their prevalence, most KRAB-ZNF genes remain
completely uncharacterized in their function.
All the reported male patients presented hypospadias and shared
the deletion of Wilms tumor interacting protein (WTIP), that is
located outside from the MOR common to all cases (Figure 3). This
gene is indeed a strong candidate for the observed sexual development
disorder as its product interacts with WT1 (Wilms tumor 1), a gene
having a well-known role in proper sex development.8 The Wt1
protein has an essential role in the mammalian urogenital develop-
ment, and WT1 mutations in humans lead to a variety of disorders,
including Wilms’ tumor, as well as Frasier and Denys–Drash
syndromes. Phenotypic anomalies in the latter two syndromes include
pseudohermaphroditism and sex reversal in extreme cases.9 Although
mutations for WTIP have never been reported, its well-demonstrated
interaction with WT1 makes it the best candidate in the 19q13.11
region for the observed hypospadias.10,11 Moreover, considering that
patient 127 in the DECIPHER database, also with a deletion involving
WTIP, has an XX karyotype with cryptorchid testes, we might even
hypothesize that, as most genes whose mutations are associated with
sex developmental disorders,12–14 WTIP haploinsufficiency may result
in a range of sex disorders starting from the first stage of gonadal
differentiation (XX males) to the later stages in which urethral fusion
occurs (XY males with hypospadias). This is consistent with the WT1
Figure 2 (a) Array-CGH profile of the whole chromosome 19 from patient 1. (b) Array-CGH profile of the whole chromosome 19 from patient 2.
(c) Microsatellites analysis in patient 1 and his parents showing the absence of the maternal allele in the proband.
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expression pathway both in the bipotential genital ridge and
subsequently in the differentiated gonads.11,15
Comparing all the reported patients, we confirm a significantly
more severe phenotype in patient 1 than in others concerning the
presence of a disabling movement disorder and the severity of DD/ID.
We did not identify any genes in the deleted region that can currently
be considered as an obvious candidate for dystonia that dominates the
clinical phenotype of our patient 1. Therefore, a synergistic effect
Table 1 Main clinical features in patients with deletions in 19q13.11
Malan et al1 Present report
Kulharya
et al 3 Patient 1 Patient 2 Patient 3
Schuurs-
Hoeijmakers et al 2 Patient 1 Patient 2 No./total
Size of the deletion (Mb) B11 B6.2 B4.3 B3 B2.4 B1.7 B2.6
Gender F M M M M M F
Age at the last examination 36 months 6 years 9 years 5 years 4 years 14 years 8 years
Intrauterine growth retardation + + + + + + + 7/7
Postnatal growth retardation + + + + + + + 7/7
Slender habitus + + + +  +  5/7
DD/ID + + + + + + + 7/7
Speech disturbance + + + + + + + 7/7
Microcephaly + + + + + + + 7/7
Minor facial dysmorphisms + + + + + + + 7/7
Signs of ectordermal dysplasia
Hair/eyebrows/eyelashes anomalies  + + + + + + 6/7
Aplasia cutis in midline of scalp + + + + + +  6/7
Dysplastic nails  + +  +   3/7
Teeth abnormalities (± small jaw)       + 1/7
Extremity abnormalities
Clinodactyly of the fifth finger + + + + + +  6/7
Overlapping of the toes + +      2/7
Cutaneous syndactyly   + + + +  4/7
Sacral dimple     +  + 2/7
Congenital heart disease +  +   +  3/7
Genital abnormalities
Testicular ectopia NA  + + +  NA 3/5a
Hypospadias NA + + + + + NA 5/5a
Bifid scrotum NA +   +  NA 2/5a
Single umbilical artery +  +     2/7
Dystonia      +  1/7
Epilepsy/cardiac conduction defects      +  1/7
Abbreviations: DD/ID, developmental delay/intellectual disability; F, female; M, male; NA, not applicable (for female patients).
aTotal five male patients.
Figure 3 A schematic representation of the overlapping deletions in the two patients and previously reported cases. A close view of chromosome band
19q12-q13.12 is displayed on the top. The comparison of the deleted regions in our patients and previously reported cases narrows down the overlapping
critical region from about 750kb to a size of 324kb, located on chromosome band 19q13.11, encompassing five genes. WTIP (position:
chr19:39 664720–39 683 925) and SCN1B (position: chr19:40,213,432–40,217,014) are located outside the MOR (chr19: 39 803651–40 127916).
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between several genes may be a predisposing factor for this pheno-
typical feature and, eventually, other genetic, epigenetic, or environ-
mental factors would be clearly required for the full expression of
dystonia, according to the second hit model.16 Alternatively, changed
expression/regulation of genes in the vicinity of the deletion might
contribute to the more severe phenotype of this patient, or, finally, the
deletion might unmask a recessive mutation in a gene responsible
for dystonia.17 In addition, patient 1 had a long Q–T episode related
to pimozide treatment. It is well known that neuroleptics can be
associated with increased risk of cardiac arrhythmias, including
prolongation of Q–T interval, and sudden death due to inhibition
of cardiovascular Na+, Ca2+, and K+ channels.18 The 19q13.11
deleted region includes the SCN1B gene encoding a sodium channel
b-1 subunit whose heterozygous mutations may result in generalized
epilepsy with febrile seizures plus, Brugada syndrome 5, and defects in
cardiac conduction.19,20 Thus, SCN1B haploinsufficiency might have a
synergistic effect with pimozide making manifest an otherwise
hidden abnormal repolarization defect. Consequently, this observation
might suggest that specific care in using neuroleptics should be
indicated for patients with heterozygous null mutations in voltage-
gated sodium channels. Considering all the published patients with
microdeletion of 19q13.11, 6 out 7 (Table 1) harbored the deletion of
SCN1B, however, none suffered from epilepsy or cardiac conduction
defects, at least in pediatric age, in agreement with the finding that
even deleterious ion channel mutations confer uncertain risk to
an individual depending on the other variants with which they are
combined.21
In conclusion, we have identified two patients with a deletion in
chromosome band 19q13 that allowed us to further narrow down the
critical region for 19q13.11 deletions to 324 kb. This region encom-
passes five genes. We suggest that KRAB-ZNF genes located within the
deleted region are the most likely candidate genes for the phenotypic
core of the 19q13.11 deletion syndrome, consistent with their impor-
tance for the embryonic development and cell functions. Second, we
hypothesized WTIP haploinsufficiency as responsible for hypospadias
or, to a lesser extent, for 46,XX sex reversal.
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